Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB While coronary stenting is commonly used to restore blood flow to the ...
Boston Scientific today announced FDA approval of its Agent drug-coated balloon (DCB), making it the first coronary DCB indicated for in-stent restenosis (ISR) in patients with coronary artery disease ...
The US Food and Drug Administration (FDA) has approved Boston Scientific's Agent Drug-Coated Balloon (DCB), the first coronary DCB for the treatment of coronary in-stent restenosis in patients with ...
First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- ...
WASHINGTON, DC—-Results from the full cohort of patients treated with a newly approved DCB for in-stent restenosis confirm its superiority over an uncoated balloon, and investigators say it will ...
Following the US approval of the Agent paclitaxel-coated balloon for the treatment of in-stent restenosis (ISR), the first coronary procedures with the device were performed Tuesday morning at two ...
On March 1, Boston Scientific Corp.’s Agent drug-coated balloon (DCB) became the first DCB to gain U.S. FDA approval for treatment of in-stent restenosis in patients with coronary artery disease. With ...
First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence Experience the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results